

Ref. No.: NLL/CS/2026- 645

January 23, 2026

To,  
National Stock Exchange of India Limited  
Listing Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai 400 051  
**Symbol: NECLIFE**

BSE Limited  
Corporate Relationship Department,  
P J Towers, Dalal Street,  
Mumbai 400 001  
**Scrip Code: 532649**

**Sub: Outcome of Board Meeting**

**Ref.: Regulation 30 and 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulation").**

Dear Sir/ Madam,

We wish to inform you that the Board of Directors of Nectar Lifesciences Limited ("Company") in their meeting held on Friday, January 23, 2026, have, inter-alia, noted, decided and approved the unaudited standalone and consolidated financial results for the quarter and nine months ended on December 31, 2025, which are enclosed herewith along with the limited review reports of the auditors thereon.

The Board Meeting commenced at 03:00 P.M. IST and concluded at 04:30 P.M. IST.

Kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)  
**Company Secretary & Compliance Officer**



**Independent Auditor's review report on the Quarterly and Year to date Unaudited Standalone Financial Results of the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,

The Board of Directors of,  
Nectar Lifesciences Limited,  
Village Saidpura, Tehsil Derabassi,  
Distt. S.A.S. Nagar (Mohali) Punjab

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Nectar Lifesciences Limited ("the Company") for the quarter and nine months ended Dec 31, 2025 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit.



audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Deepak Jindal & Co.  
Chartered Accountants  
Firm Regn. No. 023023N



Date: 23<sup>rd</sup> Jan 2026

Place: Chandigarh

M. No. 517148

UDIN: 26517148JJHSZK4592



**Independent Auditors' review report on the Quarterly and Year to date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended**


To

The Board of Directors

Nectar Lifesciences Limited

Village Saidpura, Tehsil Derabassi,  
Distt. S.A.S. Nagar (Mohali) Punjab

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Nectar Lifesciences Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter and nine months ended Dec 31, 2025 ("the Statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been compiled from the related consolidated financial statements and been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial & accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.




We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the subsidiaries listed as below:-
  - a. NECLIFE PT, UNIPESSOAL LDA (Inoperative)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, including the matter in which it is to be disclosed, or that it contains any material misstatement.
6. The unaudited consolidated financial results include the unaudited interim financial information of the subsidiary which have not been reviewed by their auditors, whose interim financial information excluding consolidation eliminations reflects total revenue of **Nil**, total net profit/ (loss) after tax of **Nil**, total comprehensive income of **Nil** for the quarter ended Dec 31, 2025 and nine months ended Dec 31, 2025, respectively, as considered in the Statement. The unaudited financial information has been approved and furnished to us by the management. Our conclusion in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited financial information. According to the information and explanations given to us by management, this interim financial information's are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the management.

For Deepak Jindal & Co.  
Chartered Accountants  
Firm Regn. No 023023N



(Kanav Kaushal)  
Partner  
M. No. 517148  
UDIN: 2651714800XRDNY4405

Date: 23<sup>rd</sup> Jan 2026  
Place: Chandigarh

**NECTAR LIFESCIENCES LIMITED**

Regd. Office: Shop No. 5, SL Enclave, Behind Sohi HP Gas Agency, Barwala Road, Dera Bassi, Distt. S.A.S Nagar, Punjab 140507, Tel. +91-0172-5078200, 5001687,  
 Email : cs@neclife.com, Website : [www.neclife.com](http://www.neclife.com), [CIN: L24232PB1995PLC016664]

**Statement of Standalone Financial Results for the Quarter and Nine Months ended 31.12.2025 (Rs in Lacs)**

S. No.	Particulars	Quarter Ended			9 Months Ended		Year Ended
		31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
		Restated	Restated	Restated	Restated	Restated	Restated
31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25	31-Dec-25	31-Mar-25
Restated	Restated	Restated	Restated	Restated	Restated	Restated	Restated
I	<b>Income from Operations</b>						
	Sales	-	-	-	-	-	-
	Less: GST Recovered	-	-	-	-	-	-
	<b>Revenue from Operations</b>						
	Other operating Income	-	71.45	0.63	72.08	1.88	2.50
II	Other Income	66.08	2.62	46.46	99.01	167.57	160.60
III	<b>Total Income (I + II)</b>	<b>66.08</b>	<b>74.07</b>	<b>47.09</b>	<b>171.09</b>	<b>169.45</b>	<b>163.10</b>
IV	<b>Expenses</b>						
	(a) Cost of Materials consumed	-	-	-	-	-	-
	(b) Purchase of Stock in Trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee benefits expense	60.95	2.01	2.58	65.00	6.46	8.49
	(e) Finance costs	3,022.46	-	-	3,022.47	-	-
	(f) Depreciation and amortisation expense	6.19	11.13	6.98	25.98	31.80	49.63
	(g) Other expenses	131.52	14.46	2.33	152.67	7.66	10.26
	<b>Total Expenses (IV)</b>	<b>3,221.12</b>	<b>27.60</b>	<b>11.89</b>	<b>3,266.12</b>	<b>45.92</b>	<b>68.38</b>
V	<b>Profit before exceptional items and tax (III- IV)</b>	<b>(3,155.04)</b>	<b>46.47</b>	<b>35.20</b>	<b>(3,095.03)</b>	<b>123.53</b>	<b>94.72</b>
VI	Exceptional Items (Refer Note 5A)	(8,815.13)	-	-	(8,815.13)	-	-
VII	<b>Profit from ordinary activities before tax (V - VI)</b>	<b>5,660.09</b>	<b>46.47</b>	<b>35.20</b>	<b>5,720.10</b>	<b>123.53</b>	<b>94.72</b>
VIII	<b>Tax Expense</b>						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	(1,102.49)	16.24	12.30	(1,081.52)	43.17	33.10
IX	<b>Profit for the period from continuing operations (VII-VIII)</b>	<b>6,762.58</b>	<b>30.23</b>	<b>22.90</b>	<b>6,801.62</b>	<b>80.36</b>	<b>61.62</b>
	Profit before tax for the period from discontinued operations (Refer Note 5)	(9,657.26)	(27,098.70)	1,219.58	(46,444.93)	2,489.57	(16,248.12)
	Tax expenses of discontinued operations	(4,321.65)	(9,467.90)	458.44	(17,146.63)	929.09	(4,818.42)
	<b>Profit for the period from discontinued operations</b>	<b>(5,335.61)</b>	<b>(17,630.80)</b>	<b>761.14</b>	<b>(29,298.30)</b>	<b>1,560.48</b>	<b>(11,429.70)</b>
	<b>Total Profit for the period</b>	<b>1,426.97</b>	<b>(17,600.57)</b>	<b>784.04</b>	<b>(22,496.68)</b>	<b>1,640.84</b>	<b>(11,368.08)</b>
	<b>Other Comprehensive Income</b>						
	<b>Items that will not be reclassified subsequently to profit or loss</b>						
	Remeasurement of the net defined benefit liability/asset (Net of Tax)	-	-	-	-	-	53.98
	<b>Items that will be reclassified subsequently to profit or loss</b>						
	Foreign Exchange Translation Reserve (Net of Tax)	-	-	-	-	-	-
	<b>Total Other Comprehensive Income, (Net of Tax)</b>						<b>53.98</b>
	<b>Total Comprehensive Income for the period</b>	<b>1,426.97</b>	<b>(17,600.57)</b>	<b>784.04</b>	<b>(22,496.68)</b>	<b>1,640.84</b>	<b>(11,314.10)</b>
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up)						
	a) Basic continuing operations (In Rs.)	3.02	0.01	0.01	3.03	0.04	0.03
	b) Diluted continuing operations (In Rs.)	3.02	0.01	0.01	3.03	0.04	0.03
	c) Basic discontinued operations (In Rs.)	(2.38)	(7.86)	0.34	(13.06)	0.70	(5.10)
	d) Diluted discontinued operations (In Rs.)	(2.38)	(7.86)	0.34	(13.06)	0.70	(5.10)
	e) Basic continuing & discontinued operations (In Rs.)	0.64	(7.85)	0.35	(10.03)	0.73	(5.07)
	f) Diluted continuing & discontinued operations (In Rs.)	0.64	(7.85)	0.35	(10.03)	0.73	(5.07)

Statement of Consolidated Financial Results for the Quarter and Nine months ended 31.12.2025 (Rs in Lacs)

S. No.	Particulars	Quarter Ended			9 Months Ended		Year Ended
		31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
		(Restated)	(Restated)	(Restated)	(Restated)	(Restated)	(Restated)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	<b>Income from Operations</b>						
	Sales	-	-	-	-	-	-
	Less: GST Recovered	-	-	-	-	-	-
	<b>Revenue from Operations</b>						
	Other operating Income	-	71.45	0.63	72.08	1.88	2.50
II	Other Income	66.08	2.62	46.46	99.01	167.57	160.60
III	<b>Total Income (I + II)</b>	<b>66.08</b>	<b>74.07</b>	<b>47.09</b>	<b>171.09</b>	<b>169.45</b>	<b>163.10</b>
IV	<b>Expenses</b>						
	(a) Cost of Materials consumed	-	-	-	-	-	-
	(b) Purchase of Stock in Trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee benefits expense	60.95	2.01	2.58	65.00	6.46	8.49
	(e) Finance costs	3,022.46	-	-	3,022.47	-	-
	(f) Depreciation and amortisation expense	6.19	11.13	6.98	25.98	31.80	49.63
	(g) Other expenses	131.52	14.46	2.33	152.67	7.66	10.26
	<b>Total Expenses (IV)</b>	<b>3,221.12</b>	<b>27.60</b>	<b>11.89</b>	<b>3,266.12</b>	<b>45.92</b>	<b>68.38</b>
V	<b>Profit before exceptional items and tax (III- IV)</b>	<b>(3,155.04)</b>	<b>46.47</b>	<b>35.20</b>	<b>(3,095.03)</b>	<b>123.53</b>	<b>94.72</b>
VI	Exceptional Items	(8,815.13)	-	-	(8,815.13)	-	-
VII	<b>Profit from ordinary activities before tax (V - VI)</b>	<b>5,660.09</b>	<b>46.47</b>	<b>35.20</b>	<b>5,720.10</b>	<b>123.53</b>	<b>94.72</b>
VIII	<b>Tax Expense</b>						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	(1,102.49)	16.24	12.30	(1,081.52)	43.17	33.10
IX	<b>Profit for the period from continuing operations (VII-VIII)</b>	<b>6,762.58</b>	<b>30.23</b>	<b>22.90</b>	<b>6,801.62</b>	<b>80.36</b>	<b>61.62</b>
	Profit before tax for the period from discontinued operations (Refer Note 6)	(9,657.26)	(27,098.70)	1,219.58	(46,444.93)	2,489.57	(16,248.12)
	Tax expenses of discontinued operations	(4,321.65)	(9,467.90)	458.44	(17,146.63)	929.09	(4,818.42)
	<b>Profit for the period from discontinued operations</b>	<b>(5,335.61)</b>	<b>(17,630.80)</b>	<b>761.14</b>	<b>(29,298.30)</b>	<b>1,560.48</b>	<b>(11,429.70)</b>
	<b>Total Profit for the period</b>	<b>1,426.97</b>	<b>(17,600.57)</b>	<b>784.04</b>	<b>(22,496.68)</b>	<b>1,640.84</b>	<b>(11,368.08)</b>
	<b>Other Comprehensive Income</b>						
	<b>Items that will not be reclassified subsequently to profit or loss</b>						
	Remeasurement of the net defined benefit liability/asset (Net of Tax)	-	-	-	-	-	53.98
	<b>Items that will be reclassified subsequently to profit or loss</b>						
	Foreign Exchange Translation Reserve (Net of Tax)	-	-	-	0.01	-	-
	<b>Total Other Comprehensive Income, (Net of Tax)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>0.01</b>	<b>-</b>	<b>53.98</b>
	<b>Total Comprehensive Income for the period</b>	<b>1,426.97</b>	<b>(17,600.57)</b>	<b>784.04</b>	<b>(22,496.67)</b>	<b>1,640.84</b>	<b>(11,314.10)</b>
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up)						
	a) Basic continuing operations (In Rs.)	3.02	0.01	0.01	3.03	0.04	0.03
	b) Diluted continuing operations (In Rs.)	3.02	0.01	0.01	3.03	0.04	0.03
	c) Basic discontinued operations (In Rs.)	(2.38)	(7.86)	0.34	(13.06)	0.70	(5.10)
	d) Diluted discontinued operations (In Rs.)	(2.38)	(7.86)	0.34	(13.06)	0.70	(5.10)
	e) Basic continuing & discontinued operations (In Rs.)	0.64	(7.85)	0.35	(10.03)	0.73	(5.07)
	f) Diluted continuing & discontinued operations (In Rs.)	0.64	(7.85)	0.35	(10.03)	0.73	(5.07)

## **Notes**

1. The above financial results were reviewed by Audit Committee on January 23, 2026 and approved by the Board of Directors (“Board”) of Nectar Lifesciences Limited (“Company”) in its meeting held on January 23, 2026. The statutory auditors of the Company have conducted a “Limited Review” of the above standalone and consolidated unaudited financial results for the quarter and Nine Months ended on December 31, 2025.
2. The company is exclusively in the pharmaceutical business segment.
3. Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
4. The Company has one wholly owned subsidiary, namely NECLIFE PT, UNIPESSOAL LDA, which is Inoperative during the period ended on December 31, 2025.

### **5. Discontinued Operations**

#### **A. Pharma Business**

On July 7, 2025, the Company entered into a Business Transfer Agreement (“Pharma BTA”) for the transfer of its Active Pharmaceutical Ingredients business (located at Unit 1 and Unit 2, Derabassi, Punjab) and Formulation business (located at Unit 6, Baddi, Himachal Pradesh) (“Pharma Businesses”) to Ceph Lifesciences Private Limited (“Ceph”) by way of a slump sale on a going concern basis for a total consideration of ₹127,000.00 lakhs.

The transfer of the Pharma Businesses was approved by the shareholders of the Company on August 4, 2025. The slump sale was completed on November 10, 2025. Accordingly, after working capital adjustments as per the Pharma BTA, the final consolidated consideration for Pharma BTA has been determined at ₹125,398.55 lakhs.

Out of the above amount, the Company has received ₹106,598.55 lakhs up to December 31, 2025, and the balance of ₹18,800.00 lakhs is receivable as at the quarter end. A resultant profit of ₹8,815.13 lakhs (net of current and deferred tax impact of ₹7,522.19 lakhs) arising from the sale of the Pharma Businesses has been recognised under Exceptional Items.

#### **B. Menthol Assets**

Further, the Company entered into an Asset Purchase Agreement (“APA”) dated July 7, 2025, for the transfer of assets relating to its menthol business (“Menthol Assets”) to CEPH for a consideration of ₹2,000.00 lakhs. The Menthol Asset transfer was completed on November 10, 2025. The Company has received the full consideration under the APA up to December 31, 2025.

#### **C. Capsule Business (EHGC)**

Further, on December 20, 2025, the Company entered into a Business Transfer Agreement (“Capsule BTA”) with Capnest Health Care Private Limited (“Capnest”) for Sale of its business of manufacture, distribution and marketing of Empty Hard Gelatin Capsule (located at Village

Bhatoli Kalan, Pargana Dharmpur, Tehsil Baddi, District Solan, Himachal Pradesh) ("Capsule Business") of the Company.

The transaction is for a consideration of ₹1,990.00 lakhs along with the takeover of accounts receivable and payables/ creditors by the Capnest, or such other working capital adjustments as specified in the Capsule BTA.

The sale is structured as a slump sale on a going concern basis and is subject to approval from the Government of Himachal Pradesh under Section 118 of the Himachal Pradesh Tenancy and Land Reforms Act, 1972. The transaction shall be completed in accordance with the terms set out in the Capsule BTA.

**Further, in the unaudited standalone financial results, the net results of "Pharma Businesses", "Menthol Assets" and "Capsule Business" has been disclosed separately as discontinued operation as required by Indian Accounting Standard (Ind AS) 105 – Asset Held for Sale and Discontinued Operations and Schedule III to the Companies Act, 2013. Consequently, the Company's Statement of Profit and Loss for the period ended December 31, 2025 pertains to its continuing operations only and for that purpose the results for the other reporting periods i.e., 30-Sep-25, 31-Dec-24 and 31-Mar-25, have been restated accordingly.**

Operations relating to the "Pharma Business", "Assets" and "Capsule Business" in respect of total income, total expenses and tax are being disclosed separately as Discontinued operations as part of the results below:

S. No.	Particulars	Quarter Ended			9 Months Ended		Year Ended
		31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
			Restated	Restated	Restated	Restated	Restated
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	2,173.55	9,327.02	45,433.44	39,567.08	1,24,106.60	1,66,997.36
2	Other income	1,214.40	2.56	74.98	1,221.64	143.24	336.06
3	Total expenses	13,045.21	36,428.28	44,288.84	87,233.65	1,21,760.27	1,83,581.54
4	Profit before tax	(9,657.26)	(27,098.70)	1,219.58	(46,444.93)	2,489.57	(16,248.12)
5	Tax expenses	(4,321.65)	(9,467.90)	458.44	(17,146.63)	929.09	(4,818.42)
6	Net profit after tax	(5,335.61)	(17,630.80)	761.14	(29,298.30)	1,560.48	(11,429.70)

## 6. Buy-back of Equity Shares

The Board, at its meeting held on December 03, 2025, approved a proposal for the Company to buy back its fully paid-up equity shares (face value of ₹1/- each) at a price of ₹27.00 per share for an aggregate amount of ₹8,100.00 lakhs. The buyback offer comprises the purchase of 3,00,00,000 equity shares, representing approximately 13.38% of the total paid-up equity share capital of the Company as at March 31, 2025.

The buyback is proposed to be made from all equity shareholders of the Company, excluding the Promoters and members of the Promoter Group, as on the record date, on a proportionate basis through the "Tender Offer" route, in accordance and consonance with the provisions of the

Companies Act, 2013 (“Act”) and the SEBI (Buy Back of Securities) Regulations, 2018 (“Buyback Regulations”) (including any statutory modification(s) or re-enactment thereof) and the rules made and circulars issued thereunder.

The payment for the buy back has been made by the Company on January 13, 2026 and the 3,00,00,000 equity shares has been extinguished by the National Securities Depository Limited (NSDL) on January 20, 2026.

All the relevant dates being subsequent to the financial reporting date, no effect of the buy-back has been recognized in the Statement of Profit and Loss for the quarter ended December 31, 2025.

**7. Extraordinary and Exceptional items – Refer Note 5.**

By Order of the Board of Directors  
of Nectar Lifesciences Limited

Date: 23.01.2026

(Sanjiv Goyal)

Place: Chandigarh

Chairman & Managing Director